Tirzepatide vs Retatrutide: Which is Better for Weight Loss?

Tirzepatide and retatrutide represent the current frontier of incretin-based metabolic research. Both outperform first-generation GLP-1 agonists like semaglutide, but which is superior? This evidence-based comparison examines clinical trial data, mechanisms of action, side effect profiles, and cost considerations.

Quick Comparison Table

Factor	Tirzepatide	Retatrutide
Mechanism	Dual GIP/GLP-1 agonist	Triple GIP/GLP-1/glucagon agonist
Average Weight Loss (48 weeks)	20.9% body weight	24.2% body weight
Clinical Trial Phase	Phase 3 complete, FDA approved	Phase 3 ongoing
Max Dose	15mg weekly	12mg weekly
Nausea Incidence	25-30%	30-40%
Cost (BioRelix Bali)	Rp 2,400,000 (10mg)	Rp 2,800,000 (10mg)
Availability	Widely available	Research supply only

Mechanism of Action

Tirzepatide: Dual GIP/GLP-1 Agonist

Tirzepatide activates two incretin receptors:

GLP-1 (Glucagon-Like Peptide-1): Reduces appetite, slows gastric emptying, improves insulin secretion
GIP (Glucose-Dependent Insulinotropic Polypeptide): Enhances insulin sensitivity, reduces inflammation, may improve fat metabolism

The dual mechanism provides superior weight loss compared to semaglutide (GLP-1 only). SURMOUNT-1 trial: 20.9% average body weight reduction at 15mg dose over 48 weeks.

Retatrutide: Triple GIP/GLP-1/Glucagon Agonist

Retatrutide adds a third pathway:

Glucagon receptor: Increases energy expenditure, promotes fat oxidation, raises metabolic rate

The triple mechanism produces the highest weight loss observed in clinical trials: 24.2% average body weight reduction at 12mg dose over 48 weeks (Rosenstock et al., 2023).

Key Difference: Glucagon receptor activation is what sets retatrutide apart. By increasing energy expenditure, it targets both sides of the energy balance equation (intake + output) while tirzepatide focuses primarily on intake reduction.

Clinical Trial Results

Tirzepatide: SURMOUNT-1 (n=2,539)

Dose	Average Weight Loss	% Achieving >20% Loss
5mg	15.0%	30%
10mg	19.5%	50%
15mg	20.9%	57%

Source: Jastreboff AM, et al. NEJM 2022;387(3):205-216

Retatrutide: Phase 2 Trial (n=338)

Dose	Average Weight Loss	% Achieving >20% Loss
4mg	17.3%	42%
8mg	22.8%	75%
12mg	24.2%	83%

Source: Rosenstock J, et al. Lancet 2023;402(10401):529-544

Winner: Retatrutide — 3.3% greater average weight loss at max dose. 83% of participants achieved >20% loss vs 57% on tirzepatide.

Side Effect Profiles

Gastrointestinal Effects

Side Effect	Tirzepatide (15mg)	Retatrutide (12mg)
Nausea	25-30%	30-40%
Diarrhea	15-18%	18-22%
Constipation	10-12%	8-10%
Vomiting	8-10%	10-15%

Tolerability: Both peptides have similar GI side effect profiles. Retatrutide shows slightly higher nausea/vomiting incidence due to glucagon receptor activation (which also causes nausea in some users).

Serious Adverse Events

Tirzepatide: 2.8% serious adverse events (SAEs), primarily gallbladder-related (rapid weight loss increases gallstone risk)
Retatrutide: 3.4% SAEs, similar gallbladder concerns
Discontinuation rate: Tirzepatide 6.2%, Retatrutide 8.7%

Winner: Tirzepatide — Slightly better tolerability, lower discontinuation rate. Most users tolerate both well with gradual dose titration.

Cost Comparison (Bali)

Peptide	Price (BioRelix)	Typical Maintenance Dose	Monthly Cost
Tirzepatide 10mg	Rp 2,400,000	10mg weekly (1 vial/week)	Rp 9,600,000/month
Retatrutide 10mg	Rp 2,800,000	8mg weekly (0.8 vials/week)	Rp 8,960,000/month

Cost per % weight loss:

Tirzepatide: Rp 459,800 per 1% body weight lost (20.9% loss, Rp 9.6M/month)
Retatrutide: Rp 370,200 per 1% body weight lost (24.2% loss, Rp 8.96M/month)

Winner: Retatrutide — Better cost-effectiveness despite higher per-vial price. Greater weight loss at lower weekly dose = better ROI.

Who Should Choose Which?

Choose Tirzepatide If:

First-time GLP-1 user (lower nausea incidence than retatrutide)
Prefer FDA-approved compounds (tirzepatide approved for T2D + obesity)
Have sensitive GI system (slightly better tolerability)
Target 15-20% body weight loss (tirzepatide sufficient for this goal)

Choose Retatrutide If:

Target >20% body weight loss (retatrutide shows superior results)
Previous GLP-1 use without adequate results (retatrutide's glucagon component adds new mechanism)
Willing to tolerate slightly higher nausea for better weight loss
Cost-conscious (retatrutide offers better cost per % weight lost)

Dosing Protocols

Tirzepatide Titration

Weeks 1-4: 2.5mg → Weeks 5-8: 5mg → Weeks 9-12: 7.5mg → Weeks 13+: 10-15mg

Retatrutide Titration

Weeks 1-4: 0.5mg → Weeks 5-8: 2mg → Weeks 9-12: 4mg → Weeks 13+: 8-12mg

For detailed retatrutide dosing, see our Retatrutide Dosing Guide.

Conclusion: Retatrutide Edges Ahead

Both peptides are highly effective, but retatrutide shows a modest advantage in clinical outcomes:

Weight loss: Retatrutide 24.2% vs Tirzepatide 20.9% (+3.3% advantage)
Cost-effectiveness: Retatrutide Rp 370K per 1% lost vs Tirzepatide Rp 460K
Mechanism: Retatrutide's glucagon pathway adds energy expenditure increase (tirzepatide lacks this)

Trade-off: Retatrutide has slightly higher nausea/vomiting incidence (30-40% vs 25-30%).

Verdict: For individuals seeking maximum weight loss and willing to manage GI side effects, retatrutide is the superior choice. For first-time users prioritizing tolerability, tirzepatide offers excellent results with marginally better GI profile.

Order from BioRelix (Bali)

Both include: HPLC testing (≥98% purity), bacteriostatic water, syringes, alcohol swabs, reconstitution guide. Same-day cold-chain delivery across Bali.

Contact: Telegram @biorelix

← Back to BioRelix